CVRx to Report First Quarter 2022 Financial and Operating Results and Host Conference Call

Rhea-AI Summary

CVRx announced plans to release its first quarter 2022 financial results on April 25, 2022, after market close. The company will host a conference call at 4:30 p.m. ET the same day for discussion of the results. Investors can join the call by dialing (833) 730-3980 for U.S. participants or +1 (720) 405-2140 for international callers, using the conference code 8433167. CVRx specializes in neuromodulation solutions for cardiovascular diseases, including the FDA-approved Barostim device, aimed at improving heart failure symptoms.

MINNEAPOLIS, April 12, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release first quarter 2022 financial and operating results after market close on Monday, April 25th, 2022. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day.

To listen to the conference call on your telephone, please dial (833) 730-3980 for U.S. callers, or +1 (720) 405-2140 for international callers, approximately ten minutes prior to the start time and reference conference code 8433167. To listen to a live webcast, please visit the Investors section of the CVRx website at: ir.cvrx.com/investor-relations. The webcast replay will be available on the CVRx website for 12 months following completion of the call.

About CVRx, Inc.

CVRx is focused on the development and commercialization of Barostim™, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:

Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com

Media Contact:

Erich Sandoval
Finn Partners
212.867.1762
erich.sandoval@finnpartners.com

FAQ

When will CVRx release its first quarter 2022 financial results?

CVRx plans to release its first quarter 2022 financial results after market close on April 25, 2022.

What time is the CVRx conference call to discuss financial results?

The CVRx conference call will take place at 4:30 p.m. Eastern Time on April 25, 2022.

How can I listen to the CVRx conference call?

You can listen to the CVRx conference call by dialing (833) 730-3980 for U.S. callers or +1 (720) 405-2140 for international callers, using conference code 8433167.

What is the Barostim device developed by CVRx?

Barostim is a medical technology approved by the FDA that uses neuromodulation to improve symptoms in heart failure patients.

Is Barostim approved for use outside the United States?

Yes, Barostim has received the CE Mark for use in heart failure and resistant hypertension in the European Economic Area.